Document is current
Any future updates will be listed below
-
Authors
Scandino, Riccardo
Nardone, Agostina
Casiraghi, Nicola
Galardi, Francesca
Genovese, Mattia
Romagnoli, Dario
Paoli, Marta
Biagioni, Chiara https://orcid.org/0000-0002-7908-4854
Tonina, Andrea
Migliaccio, Ilenia https://orcid.org/0000-0001-9055-4522
Pestrin, Marta
Moretti, Erica
Malorni, Luca https://orcid.org/0000-0002-4297-2997
Biganzoli, Laura https://orcid.org/0000-0001-7989-8658
Benelli, Matteo
Romanel, Alessandro https://orcid.org/0000-0003-4855-8620
-
Funding
Funding for this research was provided by:
Ministero della Salute (GR-2018-12365195, GR-2018-12365195, GR-2018-12365195)
- License Information
-
More Information
Article History
Received: 19 September 2024
Accepted: 21 February 2025
First Online: 8 March 2025
Competing interests
: Agostina Nardone; currently employed at AstraZeneca. Laura Biganzoli; honoraria: Lilly, Novartis, Pfizer, Exact Sciences, Boehringer Ingelheim; consulting or Advisory Role: AstraZeneca, Eisai, Genomic Health, Lilly, Novartis, Pfizer, Pierre Fabre, Roche, Daiichi Sankyo, Gilead Sciences, Seagen, Sanofi, Exact Sciences, Amgen, Menarini; research funding: Celgene (Inst), Genomic Health (Inst), Novartis (Inst); travel, accommodations, expenses: AstraZeneca, Daiichi Sankyo. Erica Moretti; Honoraria: Novartis, Daiichi Sankyo, Gilead; travel, accommodations, expenses: Ipsen, Novartis. Luca Malorni; honoraria: Pfizer, Novartis, Seagen; consulting or Advisory Role: Pfizer, Novartis, Seagen, Roche, Menarini Group; research funding: Pfizer, Novartis; travel, accommodations, expenses: Roche, Janssen, Gilead Sciences, Menarini Group.
: The trials included in this study received approval from the local institutional ethics committee of the Hospital of Prato and by the Area Vasta Toscana Centro local Ethics Committee (CEAVC Em.2021-CEAVC study 15108), in accordance with Helsinki Declaration. Written informed consent was prospectively obtained from all patients participating in these trials.
